Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophils

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 835-842

  Förster, Anja ^a   Falcone, Franco H ^b   Gibbs, Bernhard F ^c   Preussner, Liane M ^a   Fiebig, Britta S ^a   Altunok, Hülya ^a   Seeger, Jens M ^a   Cerny Reiterer, Sabine ^d   Rabenhorst, Anja ^a   Papenfuss, Kerstin ^e   Valent, Peter ^d,f   Kashkar, Hamid ^a   Hartmann, Karin ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Basophils; CD95; Chronic myeloid leukemia; TRAIL

Indexed keywords

DACTINOMYCIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BASOPHIL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; APOPTOSIS; BASOPHILS; CELL LINE; CELL SURVIVAL; CYCLOHEXANES; HUMANS; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84879531602     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.731600     Document Type: Article

References (39)

1. Falcone F H, Zillikens D, Gibbs B F. The 21st century renaissance of the basophil? Current insights into its role in allergic responses and innate immunity. Exp Dermatol 2006; 15: 855-864.
2. Ohnmacht C, Schwartz C, Panzer M, et al. Basophils orchestrate chronic allergic dermatitis and protective immunity against helminths. Immunity 2010; 33: 364-374.
3. Karasuyama H, Obata K, Wada T, et al. Newly appreciated roles for basophils in allergy and protective immunity. Allergy 2011; 66: 1133-1141.
4. Togias AG. Systemic immunologic and infl ammatory aspects of allergic rhinitis. J Allergy Clin Immunol 2000; 106: 247-250.
5. Denburg JA, Browman G. Prognostic implications of basophil diff erentiation in chronic myeloid leukemia. Am J Hematol 1988; 27: 110-114.
6. Hasford J, Pfi rrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998; 90: 850-858.
7. Valent P, Agis H, Sperr W, et al. Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia. Leuk Lymphoma 2008; 49: 635-638.
8. Falcone FH, Haas H, Gibbs BF. The human basophil: A new appreciation of its role in immune responses. Blood 2000; 96: 4028-4038.
9. Valent P, Schmidt G, Besemer J, et al. Interleukin-3 is a diff erentiation factor for human basophils. Blood 1989; 73: 1763-1769.
10. Valent P, Besemer J, Muhm M, et al. Interleukin 3 activates human blood basophils via high-affi nity binding sites. Proc Natl Acad Sci USA 1989; 86: 5542-5546.
11. Valent P, Bettelheim P. Cell surface structures on human basophils and mast cells: Biochemical and functional characterization. Adv Immunol 1992; 52: 333-423.
12. Yamaguchi M, Hirai K, Morita Y, et al. Hemopoietic growth factors regulate the survival of human basophils in vitro. Int Arch Allergy Immunol 1992; 97: 322-329.
13. Zheng X, Karsan A, Duronio V, et al. Interleukin-3, but not granulocyte-macrophage colony-stimulating factor and interleukin-5, inhibits apoptosis of human basophils through phosphatidylinositol 3-kinase: Requirement of NF-kappaB-dependent and -independent pathways. Immunology 2002; 107: 306-315.
14. Yoshimura C, Miyamasu M, Nagase H, et al. Glucocorticoids induce basophil apoptosis. J Allergy Clin Immunol 2001; 108: 215-220.
15. Schroeder JT, Chichester KL, Bieneman AP. Human basophils secrete IL-3: Evidence of autocrine priming for phenotypic and functional responses in allergic disease. J Immunol 2009; 182: 2432-2438.
16. Matsumoto K, Maeda A, Bochner BS, et al. Induction of apoptosis in human basophils by anti-Fas antibody treatment in vitro. Int Arch Allergy Immunol 2008; 146: 40-46.
17. Schneider E, Tonanny MB, Lisbonne M, et al. Pro-Th 1 cytokines promote Fas dependent apoptosis of immature peripheral basophils. J Immunol 2004; 172: 5262-5268.
18. Florian S, Sonneck K, Czerny M, et al. Detection of novel leukocyte diff erentiation antigens on basophils and mast cells by HLDA8 antibodies. Allergy 2006; 61: 1054-1062.
19. Kishi K. A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors. Leuk Res 1985; 9: 381-390.
20. Fisher G H, Rosenberg F J, Straus S E, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935-946.
21. Hartmann K, Wagelie-Steff en AL, von Stebut E, et al. Fas (CD95, APO-1) antigen expression and function in murine mast cells. J Immunol 1 997; 1 59: 4 006-4 014.
22. Welker P, Grabbe J, Henz BM. Diff erential expression of mast cell characteristics in human myeloid cell lines. Exp Dermatol 2004; 13: 535-542.
23. Fukuda T, Kishi K, Ohnishi Y, et al. Bipotential cell diff erentiation of KU-812: Evidence of a hybrid cell line that diff erentiates into basophils and macrophage-like cells. Blood 1987; 70: 612-619.
24. Okano H, Endo T, Shiokawa S, et al. Hemoglobin synthesis of both adult and fetal types in a human CML cell line. J Biochem 1988; 104: 162-164.
25. Nakazawa M, Mitjavila MT, Debili N, et al. KU 812: A pluripotent human cell line with spontaneous erythroid terminal maturation. Blood 1989; 73: 2003-2013.
26. Hartmann K, Beiglb ö ck F, Czarnetzki BM, et al. Effect of CC chemokines on mediator release from human skin mast cells and basophils. Int Arch Allergy Immunol 1995; 108: 224-230.
27. Yamaguchi A, Gabazza E C, Takei Y, et al. Role of thrombin in interleukin-5 expression from basophils. Biochem Biophys Res Commun 2008; 368: 116-120.
28. Krauth MT, Mirkina I, Herrmann H, et al. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy 2009; 39: 1711-1720.
29. Lin WW, Hsieh SL. Decoy receptor 3: A pleiotropic immunomodulator and biomarker for infl ammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol 2011; 81: 838-847.
30. Safa AR, Day TW, Wu CH. Cellular FLICE-like inhibitory protein (C-FLIP): A novel target for cancer therapy. Curr Cancer Drug Target 2008; 8: 37-46.
31. Didichenko SA, Spiegl N, Brunner T, et al. IL-3 induces a Pim1-dependent antiapoptotic pathway in primary human basophils. Blood 2008; 112: 3949-3958.
32. Kalousek I, Brodska B, Otevrelova P, et al. A ctinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes. Anticancer Drugs 2007; 18: 763-772.
33. Park YW, Ji JD, Lee JS, et al. Actinomycin D renders cultured synovial fi broblasts susceptible to tumour necrosis factor related apoptosisinducing ligand (TRAIL)-induced apoptosis. Scand J Rheumatol 2003; 32: 356-363.
34. Ng CP, Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: Sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol Cancer Ther 2002; 1: 1051-1058.
35. Mariani SM, Matiba B, Armandola EA, et al. Interleukin 1 betaconverting enzyme related proteases/caspases are involved in TRAILinduced apoptosis of myeloma and leukemia cells. J Cell Biol 1997; 137: 221-229.
36. Mariani SM, Krammer PH. Diff erential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 1998; 28: 973-982.
37. Steegmann JL, Odriozola J, Rodriguez-Salvanes F, et al. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: The main prognostic variables aff ecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Haematologica 1999; 84: 978-987.
38. Charles N, Hardwick D, Daugas E, et al. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med 2010; 16: 701-707.
39. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal Effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-809.